Bone Marrow Transplantation
We thank Mielcarek et al for pointing out possible limitations of our study; most of which in fact we had acknowledged in the paper:
1 ' This observation has been made in a relatively small group of patients and needs to be validated. It is not known if this observation holds true for other diagnoses, disease stages, alternative donors or PBSCT', and 'With the conflicting data in the literature, it is clear that further work is necessary to determine the effects of ABO incompatibility on the outcome of relatively homogeneous groups of patients allografted using marrow'.
The P values shown in Table 3 represented overall comparisons of ABO-matched, minor mismatched and major mismatched groups (P = 0.086 for relapse). When the minor and major mismatched groups were compared separately with the matched group, the difference in relapse rates was significant for minor/bidirectional mismatches (P = 0.051), but not for major (P = 0.22) -which is in keeping with the graft-versus-host direction isohemagglutinins seen in minor/bidirectional mismatches.
The disparate distribution of unknown FAB subtypes between ABO matched (14 of 76; 18%) and mismatched (4 of 43; 9%) was not statistically significant (P = 0.29; Fisher's exact test). Similarly, the distribution of M3 FAB subtypes between ABO matched (6 of 76; 8%) and mismatched (6 of 43; 14%) was not statistically significant (P = 0.29; 2 test). Relapse rates were higher in the ABO matched group after the exclusion of all patients with unknown FAB subtypes (P = 0.01), M3 FAB subtypes (P = 0.081), or both (P = 0.036).
There are some possible explanations for the differences between our study and that of Mielcarek et al. 2 Their study included 211 patients with AML who were allografted from HLA-matched relatives. 2 The stage at allograft was not specified -and presumably included patients other than those in first CR. Similarly, no FAB subtype or karyotype information was provided. Additionally, no doubt patients conditioned with very high intensity regimens with significantly lower relapse rates 3 were also included. A skewed distribution of any of these characteristics could easily have obscured any effect of ABO mismatch on outcome in their limited analysis.
In our opinion, further work is required to address effect of ABO incompatibility on the outcome of allogeneic transplantation.
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